Regulator of G-protein signaling 2 (RGS2) is a member of the RGS protein family, which functions as GTPase-activating proteins (GAPs) to negatively regulate G-protein-coupled receptor (GPCR) signaling. RGS2 specifically accelerates the hydrolysis of GTP bound to Gαq and Gαi subunits, terminating downstream signaling cascades involved in cardiovascular function, neurotransmission, and immune responses. Dysregulation of RGS2 has been linked to hypertension, anxiety disorders, and cancer, making it a therapeutic target of interest.
RGS2 antibodies are essential tools for studying the expression, localization, and functional roles of RGS2 in physiological and pathological contexts. These antibodies are widely used in techniques such as Western blotting (WB), immunohistochemistry (IHC), and immunocytochemistry (ICC) to detect endogenous RGS2 in tissues and cell lines. Specificity is critical, as RGS2 shares structural homology with other RGS family members. High-quality RGS2 antibodies are often validated using knockout controls or siRNA-mediated knockdown to ensure target specificity.
Commercially available RGS2 antibodies may target distinct epitopes (e.g., N-terminal or C-terminal regions) and recognize various isoforms or post-translationally modified forms. Researchers select antibodies based on experimental needs, species cross-reactivity (human, mouse, rat), and compatibility with specific applications. Recent studies using RGS2 antibodies have elucidated its roles in vasodilation, synaptic plasticity, and tumor progression, highlighting its therapeutic potential. Proper validation and optimization remain essential to minimize off-target effects and ensure reproducible results.